CL2025001372A1 - Derivados de triazinona como inhibidores de nlrp3. - Google Patents

Derivados de triazinona como inhibidores de nlrp3.

Info

Publication number
CL2025001372A1
CL2025001372A1 CL2025001372A CL2025001372A CL2025001372A1 CL 2025001372 A1 CL2025001372 A1 CL 2025001372A1 CL 2025001372 A CL2025001372 A CL 2025001372A CL 2025001372 A CL2025001372 A CL 2025001372A CL 2025001372 A1 CL2025001372 A1 CL 2025001372A1
Authority
CL
Chile
Prior art keywords
triazinone derivatives
nlrp3 inhibitors
nlrp3
inhibitors
triazinone
Prior art date
Application number
CL2025001372A
Other languages
English (en)
Inventor
Aurelie Bouche Lea
Guba Wolfgang
Jaeschke Georg
Katharina Mesch Stefanie
Martin SHANNON Jonathan
Steiner Sandra
Michael Tosstorff Andreas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2025001372A1 publication Critical patent/CL2025001372A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general (I) en donde R1, R2, R3, R4 y R5 son como se describe en la presente, composición que incluye los compuestos y métodos para usar los compuestos.
CL2025001372A 2022-11-09 2025-05-08 Derivados de triazinona como inhibidores de nlrp3. CL2025001372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22206271 2022-11-09

Publications (1)

Publication Number Publication Date
CL2025001372A1 true CL2025001372A1 (es) 2025-06-23

Family

ID=84330531

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001372A CL2025001372A1 (es) 2022-11-09 2025-05-08 Derivados de triazinona como inhibidores de nlrp3.

Country Status (15)

Country Link
EP (1) EP4615841A1 (es)
JP (1) JP2025539252A (es)
KR (1) KR20250103639A (es)
CN (1) CN120187721A (es)
AR (1) AR130984A1 (es)
AU (1) AU2023376398A1 (es)
CA (1) CA3268380A1 (es)
CL (1) CL2025001372A1 (es)
CO (1) CO2025005518A2 (es)
CR (1) CR20250185A (es)
IL (1) IL319011A (es)
MX (1) MX2025004959A (es)
PE (1) PE20251696A1 (es)
TW (1) TW202434581A (es)
WO (1) WO2024099992A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250162889A (ko) * 2023-03-23 2025-11-19 청두 제니타르 바이오메디컬 테크놀로지 컴퍼니 리미티드 트리아진계 화합물 및 이의 용도
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025261430A1 (zh) * 2024-06-21 2025-12-26 成都赜灵生物医药科技有限公司 苯并噻吩类氘代化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
JP2023523756A (ja) * 2020-04-30 2023-06-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規なトリアジノインドール化合物

Also Published As

Publication number Publication date
TW202434581A (zh) 2024-09-01
CN120187721A (zh) 2025-06-20
WO2024099992A1 (en) 2024-05-16
PE20251696A1 (es) 2025-07-02
AU2023376398A1 (en) 2025-02-13
JP2025539252A (ja) 2025-12-04
EP4615841A1 (en) 2025-09-17
CO2025005518A2 (es) 2025-05-19
CA3268380A1 (en) 2024-05-16
AR130984A1 (es) 2025-02-05
KR20250103639A (ko) 2025-07-07
MX2025004959A (es) 2025-06-02
IL319011A (en) 2025-04-01
CR20250185A (es) 2025-06-10

Similar Documents

Publication Publication Date Title
CO2023016204A2 (es) Inhibidores de nlrp3
CO2025005518A2 (es) Derivados de triazinona como inhibidores de nlrp3
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
CO2023004195A2 (es) Compuestos heterocíclicos
CO2023016212A2 (es) Derivados de triazina y su uso en el tratamiento del cáncer
CL2023003154A1 (es) Compuestos heterocíclicos
CL2024001106A1 (es) Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3
CO2023010212A2 (es) Derivados novedosos de pirimidin-2-il sulfonamida
CO2025007108A2 (es) Compuestos novedosos como moduladores de la inhibición de nlrp3
CL2022002661A1 (es) Derivados de benzodiazepinas como pam de gaba a gamma1
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
AR131282A1 (es) Compuestos novedosos
CO2022002336A2 (es) Compuestos heterocíclicos
AR131006A1 (es) Compuestos novedosos
CO2025003256A2 (es) Derivados novedosos deuterados de pirimidin-2-il sulfonamida
CL2024001481A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CL2025000126A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
AR132456A1 (es) Compuestos novedosos
CL2025000125A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
AR132377A1 (es) Compuestos novedosos
CO2025019059A2 (es) Derivados de triazina como inhibidores de nlrp3
CL2025000381A1 (es) Compuestos derivados bicíclicos de tetrahidrotiazepina
AR133375A1 (es) Compuestos novedosos
CO2025001103A2 (es) Derivados de tetrahidrotiazepina bicíclicos